Therapy Areas: Inflammatory Diseases
Physiomics secures new modelling contract with Numab Therapeutics
28 January 2026 - Mathematical modelling, data science and biostatistics company Physiomics plc (AIM: PYC) announced on Wednesday that it has been awarded a new contract by long-standing client Numab ...
Simcere Pharmaceutical enter licence and collaboration agreement with Boehringer Ingelheim
28 January 2026 - China-based Simcere Pharmaceutical Group Ltd (HKEX:2096), announced on Tuesday that it has signed a licence and collaboration agreement with Germany-based pharmaceutical company Boeh...
Insilico Medicine's ISM8969 receives US FDA IND approval for Parkinson's Disease
26 January 2026 - Insilico Medicine (HK:3696), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), announced on Friday that ISM8969, an orally av...
NeuroSense Therapeutics granted US patent protection for use of PrimeC combination in Alzheimer's disease
22 January 2026 - NeuroSense Therapeutics Ltd (NASDAQ:NRSN), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, announced on Wednesday that ...
LEO Pharma advances delgocitinib cream into phase 3 trial for lichen sclerosus
21 January 2026 - Danish pharmaceutical company LEO Pharma A/S said on Wednesday that it has initiated the phase 3 DELTA CARE 1 trial to evaluate the efficacy and safety of Anzupgo (delgocitinib) crea...
HistoIndex partners Houston Research Institute
21 January 2026 - HistoIndex, a Singapore-based developer of AI-driven digital pathology solutions for chronic liver disease, said on Tuesday that it has formed a strategic partnership with Houston Re...